OBJECTIVE AND DESIGN: The present study aims at evaluating the influence of genetic polymorphisms on antiretroviral therapy (ART)-associated lipodystrophy. We included in the study 255 ICoNA. patients and we assessed the distribution of Fas -670 AG polymorphism, ApoC3 -455 CT and -482 CT polymorphisms, C161T silent substitution in the PPAR gamma gene, the Adrenergic beta3 Receptor (ARbeta3) codon 64 TC variant, and two polymorphisms in the Adrenergic beta2 Receptor (ARbeta2) codon 16 AG and codon 27 CG. Crude rates of lipoatrophy and fat accumulation and adjusted relative rates were calculated using Poisson regression. RESULTS: In a multivariate model after adjusting for gender, HIV exposure, age, current viral load, hepatitis C virus (HCV) serology, nucleoside reverse-transcriptase inhibitor (NRTI) pair/'third drugs' currently used, months of pre-highly active antiretroviral therapy (HAART) exposures to NRTI, the following genotypes resulted protective against lipoatrophy: ApoC3 -455 CC genotype [adjusted relative risks (ARR) 0.2, 95% confidence interval (CI) 0.046-0.91 vs CT/TT, P = 0.037], ARbeta3 codon 64 TT genotype (ARR 0.39, 95% CI 0.14-1.06 vs TC/CC, P = 0.066), and Fas -670 GG genotype (ARR 0.51, 95% CI 0.26-1.01 vs AG/AA, P = 0.053). With regard to fat accumulation, in the multivariate model, the ARbeta2 codon 27 CC genotype resulted protective (ARR 0.21, 95% CI 0.08-0.51 vs CG/GG, P = 0.0006), whereas the ARbeta2 codon 16 AA genotype resulted associated with higher risk (ARR 3.72, 95% CI 1.58-8.76 vs AG/GG, P = 0.0026). CONCLUSION: Our study suggests that genetic polymorphisms of genes involved in apoptosis and adipocyte metabolism are significantly related to ART associated lipodystrophy. Particularly, we evidenced a role for ApoC3 -455 in lipoatrophy and for the two variants of ARbeta2 in fat accumulation.
OBJECTIVE AND DESIGN: The present study aims at evaluating the influence of genetic polymorphisms on antiretroviral therapy (ART)-associated lipodystrophy. We included in the study 255 ICoNA. patients and we assessed the distribution of Fas -670 AG polymorphism, ApoC3 -455 CT and -482 CT polymorphisms, C161T silent substitution in the PPAR gamma gene, the Adrenergic beta3 Receptor (ARbeta3) codon 64 TC variant, and two polymorphisms in the Adrenergic beta2 Receptor (ARbeta2) codon 16 AG and codon 27 CG. Crude rates of lipoatrophy and fat accumulation and adjusted relative rates were calculated using Poisson regression. RESULTS: In a multivariate model after adjusting for gender, HIV exposure, age, current viral load, hepatitis C virus (HCV) serology, nucleoside reverse-transcriptase inhibitor (NRTI) pair/'third drugs' currently used, months of pre-highly active antiretroviral therapy (HAART) exposures to NRTI, the following genotypes resulted protective against lipoatrophy: ApoC3 -455 CC genotype [adjusted relative risks (ARR) 0.2, 95% confidence interval (CI) 0.046-0.91 vs CT/TT, P = 0.037], ARbeta3 codon 64 TT genotype (ARR 0.39, 95% CI 0.14-1.06 vs TC/CC, P = 0.066), and Fas -670 GG genotype (ARR 0.51, 95% CI 0.26-1.01 vs AG/AA, P = 0.053). With regard to fat accumulation, in the multivariate model, the ARbeta2 codon 27 CC genotype resulted protective (ARR 0.21, 95% CI 0.08-0.51 vs CG/GG, P = 0.0006), whereas the ARbeta2 codon 16 AA genotype resulted associated with higher risk (ARR 3.72, 95% CI 1.58-8.76 vs AG/GG, P = 0.0026). CONCLUSION: Our study suggests that genetic polymorphisms of genes involved in apoptosis and adipocyte metabolism are significantly related to ART associated lipodystrophy. Particularly, we evidenced a role for ApoC3 -455 in lipoatrophy and for the two variants of ARbeta2 in fat accumulation.
Authors: L Egaña-Gorroño; E Martínez; P Domingo; M Loncà; T Escribà; J Fontdevila; F Vidal; E Negredo; J M Gatell; M Arnedo Journal: Antimicrob Agents Chemother Date: 2014-08-25 Impact factor: 5.191
Authors: Stella Aslibekyan; Howard W Wiener; Peter J Havel; Kimber L Stanhope; Diane M O'Brien; Scarlett E Hopkins; Devin M Absher; Hemant K Tiwari; Bert B Boyer Journal: J Nutr Date: 2014-01-29 Impact factor: 4.798
Authors: Marguerite Ryan Irvin; Sadeep Shrestha; Yii-Der I Chen; Howard W Wiener; Talin Haritunians; Laura K Vaughan; Hemant K Tiwari; Kent D Taylor; Rebecca Scherzer; Michael S Saag; Carl Grunfeld; Jerome I Rotter; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2011-12 Impact factor: 2.089
Authors: M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza Journal: Clin Exp Immunol Date: 2016-08-09 Impact factor: 4.330
Authors: Steve Innes; Eva Schulte-Kemna; Mark F Cotton; Ekkehard Werner Zöllner; Richard Haubrich; Hartwig Klinker; Xiaoying Sun; Sonia Jain; Clair Edson; Margaret van Niekerk; Emily Ryan Innes; Helena Rabie; Sara H Browne Journal: Pediatr Infect Dis J Date: 2013-06 Impact factor: 2.129
Authors: Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown Journal: Clin Infect Dis Date: 2016-01-20 Impact factor: 9.079